Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 5 (2008), Issue 11 (November)

1. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
   J Natl Cancer Inst, 100(21): 1519-29. [Abstract] [Full-text]
2. The differential response to chemotherapy of ovarian metastases from colorectal carcinoma.
   Eur J Surg Oncol, 34(12): 1335-9. [Abstract] [Full-text]
3. New insights into the pathogenesis of serous ovarian cancer and its clinical impact.
   J Clin Oncol, 26(32): 5284-93. [Abstract] [Full-text]
4. B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer.
   Clin Immunol, 129(3): 471-81. [Abstract] [Full-text]
5. Glucose-regulated protein 78 as a novel effector of BRCA1 for inhibiting stress-induced apoptosis.
   Oncogene, 27(53): 6782-9. [Abstract] [Full-text]
6. Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer.
   J Pharmacol Exp Ther, 327(3): 673-82. [Abstract] [Full-text]
7. Integrin alphavbeta3-mediated transcriptional regulation of TIMP-1 in a human ovarian cancer cell line.
   Biochem Biophys Res Commun, 377(2): 479-83. [Abstract] [Full-text]
8. PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival.
   Cancer Res, 68(22): 9302-10. [Abstract] [Full-text]
9. Small interfering RNA molecules targeting endothelin-converting enzyme-1 inhibit endothelin-1 synthesis and the invasive phenotype of ovarian carcinoma cells.
   Cancer Res, 68(22): 9265-73. [Abstract] [Full-text]
10. The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors.
    Arch Gynecol Obstet, 279(1): 53-6. [Abstract] [Full-text]
11. Removal of enormous bilateral mucinous cystadenomas of the ovaries with abdominal plastic reconstruction.
    Arch Gynecol Obstet, 279(1): 65-7. [Abstract] [Full-text]
12. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells.
    J Natl Cancer Inst, 100(22): 1630-42. [Abstract] [Full-text]
13. Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.
    J Clin Oncol, 26(33): 5393-400. [Abstract] [Full-text]
14. Cysteine-rich 61 (CYR61) inhibits cisplatin-induced apoptosis in ovarian carcinoma cells.
    Biotechnol Lett, 31(1): 23-8. [Abstract] [Full-text]
15. S100P sensitizes ovarian cancer cells to carboplatin and paclitaxel in vitro.
    Cancer Lett, 272(2): 277-84. [Abstract] [Full-text]
16. NK cells are migrated and indispensable in the anti-tumor activity induced by CCL27 gene therapy.
    Cancer Immunol Immunother, 58(2): 291-9. [Abstract] [Full-text]
17. 14-3-3 zeta protein secreted by tumor associated monocytes/macrophages from ascites of epithelial ovarian cancer patients.
    Cancer Immunol Immunother, 58(2): 247-58. [Abstract] [Full-text]
18. Receiving inconclusive genetic test results: an interpretive description of the BRCA1/2 experience.
    Res Nurs Health, 31(6): 553-62. [Abstract] [Full-text]
19. Assessing the impact of tissue devitalization time on genome-wide gene expression analysis in ovarian tumor samples.
    Diagn Mol Pathol, 17(4): 200-6. [Abstract] [Full-text]
20. Body size in early life and risk of epithelial ovarian cancer: results from the Nurses' Health Studies.
    Br J Cancer, 99(11): 1916-22. [Abstract] [Full-text]
21. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells.
    J Clin Invest, 118(12): 3917-29. [Abstract] [Full-text]
22. Autophagy-induced tumor dormancy in ovarian cancer.
    J Clin Invest, 118(12): 3837-40. [Abstract] [Full-text]
23. Non-DNA-binding platinum anticancer agents: Cytotoxic activities of platinum-phosphato complexes towards human ovarian cancer cells.
    Proc Natl Acad Sci U S A, 105(47): 18314-9. [Abstract] [Full-text]
24. A longitudinal investigation of psychological morbidity in patients with ovarian cancer.
    Br J Cancer, 99(11): 1794-801. [Abstract] [Full-text]
25. Isothiocyanate NB7M causes selective cytotoxicity, pro-apoptotic signalling and cell-cycle regression in ovarian cancer cells.
    Br J Cancer, 99(11): 1823-31. [Abstract] [Full-text]
26. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
    J Clin Oncol, 26(34): 5530-6. [Abstract] [Full-text]
27. Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis.
    Int J Cancer, 124(3): 553-61. [Abstract] [Full-text]
28. Breast cancer susceptibility alleles and ovarian cancer risk in 2 study populations.
    Int J Cancer, 124(3): 729-33. [Abstract] [Full-text]
29. The cell of origin of ovarian epithelial tumours.
    Lancet Oncol, 9(12): 1191-7. [Abstract] [Full-text]
30. Squamous-cell carcinoma in mature cystic teratoma of the ovary: systematic review and analysis of published data.
    Lancet Oncol, 9(12): 1173-80. [Abstract] [Full-text]
31. Nelfinavir induces TRAIL receptor upregulation in ovarian cancer cells.
    Biochem Biophys Res Commun, 377(4): 1309-14. [Abstract] [Full-text]
32. Hereditary ovarian cancer.
    Crit Rev Oncol Hematol, 69(1): 28-44. [Abstract] [Full-text]
33. Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer.
    Crit Rev Oncol Hematol, 69(1): 12-27. [Abstract] [Full-text]

© 2004-2010 Ovarian Cancer Research Today. All Rights Reserved.